Personalis (PSNL) Competitors $6.30 +0.21 (+3.45%) (As of 03:27 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends PSNL vs. FTRE, TDOC, VRDN, AHCO, CDNA, PNTG, AVAH, CSTL, AGL, and GRALShould you be buying Personalis stock or one of its competitors? The main competitors of Personalis include Fortrea (FTRE), Teladoc Health (TDOC), Viridian Therapeutics (VRDN), AdaptHealth (AHCO), CareDx (CDNA), The Pennant Group (PNTG), Aveanna Healthcare (AVAH), Castle Biosciences (CSTL), agilon health (AGL), and Grail (GRAL). These companies are all part of the "healthcare" industry. Personalis vs. Fortrea Teladoc Health Viridian Therapeutics AdaptHealth CareDx The Pennant Group Aveanna Healthcare Castle Biosciences agilon health Grail Personalis (NASDAQ:PSNL) and Fortrea (NASDAQ:FTRE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, community ranking, analyst recommendations, institutional ownership, media sentiment, profitability and earnings. Do insiders and institutionals have more ownership in PSNL or FTRE? 61.9% of Personalis shares are held by institutional investors. 4.1% of Personalis shares are held by insiders. Comparatively, 0.1% of Fortrea shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts rate PSNL or FTRE? Personalis currently has a consensus price target of $7.31, suggesting a potential upside of 20.07%. Fortrea has a consensus price target of $23.30, suggesting a potential upside of 24.27%. Given Fortrea's higher probable upside, analysts clearly believe Fortrea is more favorable than Personalis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Personalis 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Fortrea 1 Sell rating(s) 11 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.92 Does the media refer more to PSNL or FTRE? In the previous week, Personalis had 11 more articles in the media than Fortrea. MarketBeat recorded 14 mentions for Personalis and 3 mentions for Fortrea. Fortrea's average media sentiment score of 0.58 beat Personalis' score of 0.31 indicating that Fortrea is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Personalis 0 Very Positive mention(s) 6 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Fortrea 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings and valuation, PSNL or FTRE? Fortrea has higher revenue and earnings than Personalis. Fortrea is trading at a lower price-to-earnings ratio than Personalis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPersonalis$87.49M4.92-$108.30M-$1.68-3.63Fortrea$2.98B0.57-$3.40M-$3.42-5.48 Which has more volatility and risk, PSNL or FTRE? Personalis has a beta of 1.88, suggesting that its share price is 88% more volatile than the S&P 500. Comparatively, Fortrea has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500. Is PSNL or FTRE more profitable? Fortrea has a net margin of -10.99% compared to Personalis' net margin of -104.52%. Fortrea's return on equity of 2.00% beat Personalis' return on equity.Company Net Margins Return on Equity Return on Assets Personalis-104.52% -66.07% -41.34% Fortrea -10.99%2.00%0.80% Does the MarketBeat Community prefer PSNL or FTRE? Personalis received 106 more outperform votes than Fortrea when rated by MarketBeat users. Likewise, 66.86% of users gave Personalis an outperform vote while only 25.58% of users gave Fortrea an outperform vote. CompanyUnderperformOutperformPersonalisOutperform Votes11766.86% Underperform Votes5833.14% FortreaOutperform Votes1125.58% Underperform Votes3274.42% SummaryPersonalis beats Fortrea on 11 of the 18 factors compared between the two stocks. Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get Personalis News Delivered to You Automatically Sign up to receive the latest news and ratings for PSNL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PSNL vs. The Competition Export to ExcelMetricPersonalisMedical laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$430.25M$2.84B$5.24B$9.28BDividend YieldN/A15.37%5.12%4.28%P/E Ratio-3.6216.0387.5417.25Price / Sales4.92267.501,164.33121.12Price / CashN/A472.1143.3837.82Price / Book2.315.094.844.94Net Income-$108.30M-$32.86M$121.05M$225.76M7 Day Performance15.78%1.18%2.49%3.92%1 Month Performance63.27%-1.21%17.57%1.71%1 Year Performance248.00%8.65%28.57%15.79% Personalis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PSNLPersonalis4.0353 of 5 stars$6.30+3.4%$7.31+16.1%+315.7%$445.08M$87.49M-3.75400FTREFortrea2.4949 of 5 stars$18.72-2.8%$23.30+24.5%-46.2%$1.68B$2.98B-5.4718,000TDOCTeladoc Health3.736 of 5 stars$9.19-2.6%$12.24+33.2%-56.9%$1.58B$2.59B-1.595,600Short Interest ↓VRDNViridian Therapeutics2.832 of 5 stars$19.61+3.0%$35.70+82.0%-14.0%$1.55B$302,000.00-4.5550AHCOAdaptHealth3.2966 of 5 stars$10.09-1.8%$11.67+15.6%+41.7%$1.36B$3.26B-6.1210,700Positive NewsCDNACareDx4.243 of 5 stars$21.03+2.0%$29.60+40.8%+79.2%$1.13B$312.78M-7.79740Short Interest ↓Positive NewsPNTGThe Pennant Group4.6673 of 5 stars$27.06-1.2%$37.20+37.5%+90.5%$929.46M$652.30M39.795,791AVAHAveanna Healthcare0.8565 of 5 stars$4.48-2.2%$4.27-4.8%+61.9%$865.65M$1.98B-13.1833,500CSTLCastle Biosciences3.6593 of 5 stars$27.45-0.3%$39.71+44.7%+28.2%$768.79M$311.88M137.26540Short Interest ↓Positive NewsAGLagilon health3.04 of 5 stars$1.85-6.1%$4.28+131.5%-84.7%$762.23M$5.59B-1.971,117Short Interest ↓GRALGrail0.4823 of 5 stars$19.00+3.5%$16.00-15.8%N/A$638.42M$117.67M0.001,360Short Interest ↑ Related Companies and Tools Related Companies FTRE Competitors TDOC Competitors VRDN Competitors AHCO Competitors CDNA Competitors PNTG Competitors AVAH Competitors CSTL Competitors AGL Competitors GRAL Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PSNL) was last updated on 12/26/2024 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredThe Key to Feeding 8.1 Billion PeopleImagine a mineral so small it fits in the palm of your hand... yet its potential could transform the world's f...i2i Marketing Group, LLC | SponsoredIs Jeff Bezos Crowning the Next Nvidia?It doesn't matter what you think about AI... Because Jeff Bezos's massive load-up on one tiny tech company ...InvestorPlace | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Personalis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Personalis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
